Fluorouracil 50 mg/ml Solution for Injection or Infusion
Sponsors
Gilead Sciences Inc., Bristol-Myers Squibb Services Unlimited Company, Pfizer Inc., Groupe Oncologie Radiotherapie Tete Cou, Cancer Trials Ireland
Conditions
Colorectal cancer (BRAF V600E-mutant mCRC)Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or LessLocally Advanced Pancreatic CancerMetastatic Colorectal Cancer (mCRC)Pan tumorPatients with 1-3 positive NodesPatients with metastatic pancreatic ductal adenocarcinoma.squamous cell carcinomas of the larynx or hypopharynx locally advance
Phase 2
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
CompletedCTIS2022-500177-13-00
Start: 2023-06-02End: 2024-06-26Target: 46Updated: 2024-04-02
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Start: 2020-05-05Target: 307Updated: 2026-01-19
Prospective phase IIb study to evaluate the efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic cancer - ECT-LAPC Laparoscopic
Not yet recruitingCTIS2024-519067-17-00
Target: 90Updated: 2024-12-02
Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line treatment – A non-comparative, randomized phase II PANORAMIX GERCOR G-116 PRODIGE 105 study
Not yet recruitingCTIS2024-517766-41-00
Target: 142Updated: 2025-05-27
Phase 3
C4221015 - AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY
VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E MUTANT COLORECTAL CANCER
Active, not recruitingCTIS2023-509405-77-00
Start: 2021-02-16Target: 300Updated: 2026-01-26
Phase III trial of laryngeal preservation comparating Induction chemotherapy with cisplatin, 5-fluorouracil and docetaxel (TPF) followed by radiotherapy and concomitant administration of radiotherapy with cisplatin (SALTORL).
Active, not recruitingCTIS2024-513976-16-00
Start: 2015-06-26Target: 256Updated: 2024-07-15
SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive Nodes Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or less
Active, not recruitingCTIS2024-516801-22-00
Start: 2012-04-26Target: 141Updated: 2025-05-20